MedTrace Logo

Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects

NCT04111523 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2021-05-06

No results posted yet for this study

Summary

This study is a single-dose incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.

Conditions

  • Cerebral Apoplexy

Interventions

DRUG

SY-007

A single dose of SY-007 or placebo injection(1mg-45mg)

Sponsors & Collaborators

  • Suzhou Yabao Pharmaceutical R&D Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zheng Li, Doctor · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2020-05-26
Completion
2020-05-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04111523 on ClinicalTrials.gov